- Home
- LSF vs COEP Comparison
LSF vs COEP Comparison
Compare LSF & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | LSF | COEP |
|---|---|---|
| Founded | 2015 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 24.3M | 100.4M |
| IPO Year | 2020 | N/A |
Fundamental Metrics
Financial Performance| Metric | LSF | COEP |
|---|---|---|
| Price | $2.07 | $14.36 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $12.00 | N/A |
| AVG Volume (30 Days) | ★ 95.9K | 91.6K |
| Earning Date | 11-10-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $48,146,862.00 | $500,996.00 |
| Revenue This Year | $18.05 | N/A |
| Revenue Next Year | $17.53 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 17.73 | N/A |
| 52 Week Low | $2.07 | $2.31 |
| 52 Week High | $8.96 | $21.41 |
Technical Indicators
Market Signals| Indicator | LSF | COEP |
|---|---|---|
| Relative Strength Index (RSI) | 29.58 | 41.33 |
| Support Level | $2.02 | $14.82 |
| Resistance Level | $2.52 | $16.60 |
| Average True Range (ATR) | 0.19 | 1.51 |
| MACD | 0.04 | -0.26 |
| Stochastic Oscillator | 6.58 | 9.62 |
Price Performance
Historical ComparisonAbout LSF Laird Superfood Inc.
Laird Superfood Inc is engaged in the business of manufacturing and marketing differentiated plant-based and functional foods. The product portfolio includes Coffee creamers, Hydration products and beverage-enhancing supplements, Harvest snacks and various other food items, and Coffee, tea, and hot chocolate products.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.